Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : India Coffee House -- Ignore unavailable to you. Want to Upgrade?

To: Mohan Marette who wrote (3986)	4/2/1999 11:39:00 AM
From: Mohan Marette	Read Replies (1) \| Respond to of 12475

Merck and Ranbaxy near licensing pact. deal for prostrate cancer treatment molecule could fetch Indian company Rs 4 billion Baiju Kalesh, Gauri Kamath & Abhijit Das in Mumbai The $26.9 billion US major Merck & Co has emerged as a frontrunner in the race to license Ranbaxy Laboratories' original research molecule to treat benign prostatic hyperplasia (BHP). The deal, only the second such in India after Dr Reddy's, is expected to be a bonanza for Ranbaxy both in terms of cash inflow and prestige in the global pharmaceuticals market......<continued----> business-standard.com